Table Of Content

Contents Volume 60, Number 1, July 2005 Editors’ view The role of CYP2C and CYP3A in the disposition of Personalized medicine (or drug therapy); the patients’ 3-keto-desogestrel after administration of desogestrel: genome, the chip and the physician: L.D. Lewis T. Korhonen, A. Tolonen, J. Uusitalo, S. Lundgren, J. Jalonen & K. Laine Editors’ report 2004 Editors’ report 2004: J.K. Aronson, M.S. Lennard, Pharmacoepidemiology JM. Ritter, EJ. Begg & N.S. Baber Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the First human use UK: Cohort study using data from the UK General Clinical pharmacology of DP-b99 in healthy volunteers: Practice Research Database: S. Russmann, J.A. Kaye, First administration to humans: G. Rosenberg, |. Angel S.S. Jick & H. Jick & A. Kozak Therapeutics Pharmacodynamics Suboptimal choices and dosing of statins at start of Investigation of the effects of physiological and therapy: A.K. Mantel-Teeuwisse, O.H. Klungel, vasodilation-induced autonomic activation on the QTc T. Schalekamp, W.M.M. Verschuren, AJ. Porsius & Interval in healthy male subjects: £. Berger, K. Patel, A. de Boer S. Anwar, W. Davies & DJ. Sheridan Queen Mary Utilization of Antihypertensive Drugs Study: Levocetirizine has a longer duration of action on use of antihypertensive drug classes in the improving total nasal symptoms score than Hypertension Clinic 1996-2004: B.M.Y. Cheung, fexofenadine after single administration: F Horak, ¥L. Wong & CP. Lau PU. Zieglmayer, R. Zieglmayer, A. Kavina & P. Lemell Short reports Pharmacokinetics Deep vein thrombosis and pulmonary embolism Pharmacokinetic evidence for the induction of lopinavir reported in the Prescription Event Monitoring Study of metabolism by efavirenz: E. Dailly, C. Allavena, F. Raffi Yasmin®: H.M. Pearce, D. Layton, L.V. Wilton & & P. Jolliet SA.W. Shakir Population pharmacokinetics of imatinib mesylate in Association between CYP2C9 slow metabolizer patients with chronic-phase chronic myeloid leukaemia: genotypes and severe hypoglycaemia on medication results of a phase Ill study: H. Schmidli, B. Peng, with sulphonylurea hypoglycaemic agents: A. Holstein, G.-J. Riviere, R. Capdeville, M. Hensley, |. Gathmann, A. Plaschke, M. Ptak, E.-H. Egberts, J. El-Din, A.E. Bolton & A. Racine-Poon J. Brockméller & J. Kirchheiner Dexamethasone as a probe for vinorelbine clearance: Bosentan decreases the plasma concentration of F. Puisset, F. Dalenc, E. Chatelut, T. Cresteil, |. Lochon, sildenafil when coprescribed in pulmonary P. Tisnes & H. Roché hypertension: G.A. Paul, J.S.R. Gibbs, A.R. Boobis, A. Abbas & M.R. Wilkins Drug metabolism Cytochromes P450 and MDR] mRNA expression along Book review the human gastrointestinal tract: M. Thérn, Pharmacotherapy of Depression: edited by D.A. Ciraulo N. Finnstrém, S. Lundgren, A. Rane & L. L6df & RJ. Shader; reviewed by E. Szabadi Drug disposition Errata Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine: Letter to the editor M. Miura, H. Tada, N. Yasui-Furukori, T. Uno, Inadvertent intrathecal administration of rifampicin: K. Sugawara, T. Tateishi & T. Suzuki N. Senbaga & E.M. Davies Contents Volume 60, Number 1, July 2005 Editors’ view The role of CYP2C and CYP3A in the disposition of Personalized medicine (or drug therapy); the patients’ 3-keto-desogestrel after administration of desogestrel: genome, the chip and the physician: L.D. Lewis T. Korhonen, A. Tolonen, J. Uusitalo, S. Lundgren, J. Jalonen & K. Laine Editors’ report 2004 Editors’ report 2004: J.K. Aronson, M.S. Lennard, Pharmacoepidemiology JM. Ritter, EJ. Begg & N.S. Baber Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the First human use UK: Cohort study using data from the UK General Clinical pharmacology of DP-b99 in healthy volunteers: Practice Research Database: S. Russmann, J.A. Kaye, First administration to humans: G. Rosenberg, |. Angel S.S. Jick & H. Jick & A. Kozak Therapeutics Pharmacodynamics Suboptimal choices and dosing of statins at start of Investigation of the effects of physiological and therapy: A.K. Mantel-Teeuwisse, O.H. Klungel, vasodilation-induced autonomic activation on the QTc T. Schalekamp, W.M.M. Verschuren, AJ. Porsius & Interval in healthy male subjects: £. Berger, K. Patel, A. de Boer S. Anwar, W. Davies & DJ. Sheridan Queen Mary Utilization of Antihypertensive Drugs Study: Levocetirizine has a longer duration of action on use of antihypertensive drug classes in the improving total nasal symptoms score than Hypertension Clinic 1996-2004: B.M.Y. Cheung, fexofenadine after single administration: F Horak, ¥L. Wong & CP. Lau PU. Zieglmayer, R. Zieglmayer, A. Kavina & P. Lemell Short reports Pharmacokinetics Deep vein thrombosis and pulmonary embolism Pharmacokinetic evidence for the induction of lopinavir reported in the Prescription Event Monitoring Study of metabolism by efavirenz: E. Dailly, C. Allavena, F. Raffi Yasmin®: H.M. Pearce, D. Layton, L.V. Wilton & & P. Jolliet SA.W. Shakir Population pharmacokinetics of imatinib mesylate in Association between CYP2C9 slow metabolizer patients with chronic-phase chronic myeloid leukaemia: genotypes and severe hypoglycaemia on medication results of a phase Ill study: H. Schmidli, B. Peng, with sulphonylurea hypoglycaemic agents: A. Holstein, G.-J. Riviere, R. Capdeville, M. Hensley, |. Gathmann, A. Plaschke, M. Ptak, E.-H. Egberts, J. El-Din, A.E. Bolton & A. Racine-Poon J. Brockméller & J. Kirchheiner Dexamethasone as a probe for vinorelbine clearance: Bosentan decreases the plasma concentration of F. Puisset, F. Dalenc, E. Chatelut, T. Cresteil, |. Lochon, sildenafil when coprescribed in pulmonary P. Tisnes & H. Roché hypertension: G.A. Paul, J.S.R. Gibbs, A.R. Boobis, A. Abbas & M.R. Wilkins Drug metabolism Cytochromes P450 and MDR] mRNA expression along Book review the human gastrointestinal tract: M. Thérn, Pharmacotherapy of Depression: edited by D.A. Ciraulo N. Finnstrém, S. Lundgren, A. Rane & L. L6df & RJ. Shader; reviewed by E. Szabadi Drug disposition Errata Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine: Letter to the editor M. Miura, H. Tada, N. Yasui-Furukori, T. Uno, Inadvertent intrathecal administration of rifampicin: K. Sugawara, T. Tateishi & T. Suzuki N. Senbaga & E.M. Davies Volume 60, Number 2, August 2005 Editors’ view 176 Kidneys contribute to the extrahepatic clearance of 117 Metameta-analysis: J.K. Aronson propofol in humans, but not lungs and brain: H. Hiraoka, K. Yamamoto, S. Miyoshi, T. Morita, Pharmacodynamics K. Nakamura, Y. Kadoi, F. Kunimoto & R. Horiuchi Assessment of the effect of a single oral dose of telithromycin on sotalol-induced QT interval Therapeutics prolongation in healthy women: J.-L. Démolis, Pharmaceutical care of patients with heart failure: S. Strabach, F. Vacheron & C. Funck-Brentano A. Sadik, M. Yousif & J.C. McElnay Pharmacokinetics and Pharmacodynamics Adverse drug effects The central nervous system effects, pharmacokinetics Do nonsteroidal anti-inflammatory drugs affect the risk and safety of the NAALADase-inhibitor GP! 5693: of developing ovarian cancer? A meta-analysis: J.P. van der Post SJ. de Visser, M.L. de Kam, S. Bonovas, K. Filioussi & N.M. Sitaras M. Woelfler, D.C. Hilt, J. Vornov, E.S. Burak, E. Bortey, B.S. Slusher, T. Limsakun, A.F. Cohen & Angiotensin II receptor blocker-induces blunted taste J.M.A. van Gerven sensitivity: comparison of candesartan and valsartan: S. Tsuruoka, M. Wakaumi, T. loka, H. Yamamoto, Pharmacoepidemiology H. Ando, K. Sugimoto & A. Fujimura Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria — a population-based Drug interactions cohort study: CS. van der Hooft, G.W. 't Jong, Coadministration of gemfibrozil and itraconazole has J.P. Dieleman, K.M.C. Verhamme, only a minor effect on the pharmacokinetics of the TJ.M. van der Cammen, B.H.CH. Stricker, & CYP2C9 and CYP3A4 substrate nateglinide: M. Niemi, M.CJ.M. Sturkenboom J.T. Backman, L. Juntti-Patinen, M. Neuvonen & PJ. Neuvonen Off-label prescribing to children: attitudes and experience of general practitioners: S. Ekins-Daukes, Short Reports PJ. Helms, M.W. Taylor & J.S. McLay Profound weight loss associated with reboxetine use in a 44-year-old woman: TY.-T. Lu, A. Kupa, Statin use after acute myocardial infarction: a G. Easterbrook & A.A. Mangoni nationwide study in Denmark: J.N. Rasmussen, G.H. Gislason, S.Z. Abildstrom, S. Rasmussen, A distance-learning programme in pharmacovigilance |. Gustafsson, P. Buch, J. Friberg, L. Keber, linked to educational credits is associated with C. Torp-Pedersen, M. Madsen & S. Stender improved reporting of suspected adverse drug reactions via the UK yellow card scheme: R.C.G. Bracchi, Pharmacogenetics J. Houghton, FJ. Woods, S. Thomas, S.A. Smail & Meta-analysis of the influence of MDRI C3435T PA. Routledge polymorphism on digoxin pharmacokinetics and MDR1 gene expression: B. Chowbay, H. Li, M. David, Letter to the Editors ¥B. Cheung & EJ.D. Lee Effect of pregnancy on a measure of FMO3 activity: J. Hukkanen, D. Dempsey, P. Jacob Ill & Drug disposition N.L. Benowitz Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the Book Review involvement of CYP3A4 in brotizolam metabolism: Cardiac safety of noncardiac drugs: edited by T. Tokairin, T. Fukasawa, N. Yasui-Furukori, T. Aoshima, Morganroth and Gussack; reviewed by S.H.L. Thomas A. Suzuki, Y. Inoue, T. Tateishi & K. Otani Volume 60, Number 3, September 2005 Editors’ view Review 229 Monitoring therapy: J.K. Aronson The functional significance of genetic variation within the B,-adrenoceptor: AJ. Sandilands & Editorial commentary K.M. O’Shaughnessy 231 Changes in the usage of antihypertensive drugs: implications and prospects: M. Schachter Pharmacokinetics & Pharmacodynamics Therapeutics 244 Pharmacokinetics and pharmacodynamics of single-dose 300 Antihypertensive drug prescribing in Grampian: S. Ross triazolam: electroencephalography compared with the & MJ. Macleod Digit-Symbol Substitution Test: DJ. Greenblatt, L. Gan, JS. Harmatz & R.l. Shader 306 Concomitant use of analgesics and psychotropics in home-dwelling elderly people — Kuopio 75 + study: Pharmacokinetics S. Hartikainen, P. Mantyselkd, K. Louhivuori-Laako, Characterizing the role of enterohepatic recycling in the H. Enlund & R. Sulkava interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by Oral opioid administration and hyperalgesia in patients pharmacokinetic modelling: S. Cremers, R. Schoemaker, with cancer or chronic nonmalignant pain: |. Reznikov, E. Scholten, J. den Hartigh, J. K6nig-Quartel, D. Pud & E. Eisenberg E. van Kan, L. Paul & J. de Fijter Leflunomide in the treatment of rheumatoid arthritis. Population pharmacokinetics and association between An analysis of predictors for treatment continuation: A77 1726 plasma concentrations and disease activity E.N. van Roon, M. Hoekstra, H. Tobi, measures following administration of leflunomide to TL.TA. Jansen, H.J.B. Moens, J.R.B.J. Brouwers & people with rheumatoid arthritis: Vv Chan, B.G. Charles MA.FJ. van de Laar & S.E. Tett Short reports Population pharmacokinetics of vancomycin in patients Potential for drug interactions involving cytochrome receiving extracorporeal membrane oxygenation: P450 in patients attending palliative day care centres: a H. Mullal & S. Pooboni multicentre audit: A. Wilcock, J. Thomas, J. Frisby, M. Webster, V. Keeley, G. Finn, K. Fossey, B. Wee, Population pharmacokinetics of indinavir alone and in J. Beale & M.S. Lennard combination with ritonavir in HIV-1-infected patients: B.S. Kappelhoff, A.D.R. Huitema, S.U.C. Sankatsing, 330 Ziprasidone decreases cortisol excretion in healthy PL. Meenhorst, E.CM. Van Gorp, J.W. Mulder, J.M. Prins subjects: A. Meier, A.-C. Neumann, W. Jordan, & J.H. Beynen G. Huether, A. Rodenbeck, E. Riither & S. Cohrs Drug interactions Effects of grapefruit juice on the absorption of The effect of cimetidine or omeprazole on the levothyroxine: J.J. Lilia, K. Laitinen & PJ. Neuvonen pharmacokinetics of escitalopram in healthy subjects: D. Malling, M.N. Poulsen & B. Sagaard Letter to the Editors An unexpected response to intravenous hydrocortisone Therapeutic drug monitoring succinate in an asthmatic patient: GP Currie, Therapeutic drug monitoring of atazanavir: surveillance E. Paterson, F. Keenan, S. Nath & SJ. Watt of pharmacotherapy in the clinic: JE. Ray, D. Marriott, M.T. Bloch & AJ. McLachlan Erratum Volume 60, Number 4, October 2005 Editors’ view a population model analysis: P. Sanchez-Pena, 345 One hundred years of atrial fibrillation: J.K. Aronson J.-S. Hulot, S. Urien, A. Ankri, J.-P. Collet R. Choussat P. Lechat & G. Montalescot Systematic review Pharmacokinetics 347 Rhythm vs. rate control of atrial fibrillation meta- Effects of food and formulation on the relative analysed by number needed to treat: CR. Kumana, bioavailability of bismuth biskalcitrate, metronidazole, B.M.Y. Cheung, G.TY. Cheung, T. Ovedal, B. Pederson and tetracycline given for Helicobacter pylori & IJ. Lauder eradication: J. Spénard, C. Aumais, J. Massicotte, J.-S. Brunet, C. Tremblay, M. Grace & M. Lefebvre Pharmacodynamics Population pharmacokinetics of lopinavir in combination 355 Preservation of platelet responsiveness to nitroglycerine with ritonavir in HIV-1-infected patients: despite development of vascular nitrate tolerance: K.M.L. Crommentuyn, B.S. Kappelhoff, J.W. Mulder, A.S. Holmes, Y¥.Y. Chirkov, S.R. Willoughby, S. Poropat, A.TA. Mairuhu, E.C.M. van Gorp, PL. Meenhorst, J. Pereira & J.D. Horowitz A.D.R. Huitema & J.H. Beijnen 364 Anti-factor Xa kinetics after intravenous enoxaparin in Population pharmacokinetic analysis for nelfinavir and patients undergoing percutaneous coronary intervention: its metabolite M8 in virologically controlled HIV-infected patients on HAART: X. Panhard, C. Goujard, D. Beyer, M.N. Bizot, Q. Jiang, MJ. Allison & M. Legrand, A. M. Taburet, B. Diquet, F Mentré and R.L. Schmouder the COPHAR 1-ANRS study group Therapeutics Pharmacodynamics & pharmacokinetics 438 Inappropriate initial treatment of secondary intra- Within- and between- subject variability in methadone abdominal infections leads to increased risk of clinical pharmacokinetics and pharmacodynamics in failure and costs: M.CJ.M. Sturkenboom, WG. Goettsch, methadone maintenance subjects: J. Hanna, G. Picelli, Bas in ‘t Veld, D.D. Yin, R.B. de Jong, D.J.R. Foster, A. Salter, AA. Somogyi, J.M. White & PM.N.Y.H. Go & R.M.C. Herings F. Bochner Clinical toxicology Pharmacogenetics 444 Co-proxamol overdose is associated with a 10-fold No positive association between adrenergic receptor excess mortality compared with other paracetamol variants of o2-Del322—325, B,Ser49, B,Arg389 and the combination analgesics: R. Afshari, AM. Good, risk for heart failure in the Japanese population: S.RJ. Maxwell & D.N. Bateman S. Nonen, H. Okamoto, M. Akino, Y¥. Matsui, Y. Fujio, M. Yoshiyama, Y. Takemoto, J. Yoshikawa, Short report J. Azuma & A. Kitabatake The quality of information on monitoring for haematological adverse drug reactions: RE. Ferner, Allele and genotype frequencies of CYP2C9 in a J. Coleman, M. Pirmohamed, S.A. Constable & Korean population: J.-W/ Bae, H.-K. Kim, J.-H. Kim, A. Rouse S.-l. Yang, M.-J. Kim, C.-G. Jang, ¥.-S. Park & S.-Y. Lee Letter to the editors Drug disposition Estimation of time devoted to adverse drug reactions S-Naproxen and desmethylnaproxen glucuronidation by assessment in an internal medicine department: human liver microsomes and recombinant human N. Tavassoli, H. Bagheri, L. Sailler, R_ Benkemoun, UDP-glucuronosyltransferases (UGT): role of UGT2B7 in J.-L. Montastruc & P. Arlet the elimination of naproxen: K. Bowalgaha, DJ. Elliot Pl. Mackenzie, K.M. Knights, S. Swedmark & Book review J.O. Miners Side-effects of Drugs Annual 27: edited by J.K. Aronson; reviewed by R.E. Ferner Drug interaction Pharmacokinetic interaction between verapamil and Erratum everolimus in healthy subjects: J. M. Kovarik, Volume 60, Number 5, November 2005 Editors’ view K.E. Culm-Merdek, L.L. von Moltke, J.S. Harmatz & Prescribing statins: J.K. Aronson DJ. Greenblatt Pharmacodynamics Interactions The effect of tadalafil on the time to exercise-induced Effects of grapefruit juice on the pharmacokinetics of myocardial ischaemia in subjects with coronary artery pitavastatin and atorvastatin: H. Ando, S. Tsuruoka, disease: D. Patterson, R. Kloner, M. Effron, J. Emmick, H. Yanagihara, K.-l. Sugimoto, M. Miyata, ¥. Yamazoe, A. Bedding, M. Warner, M. Mitchell, S. Braat & T. Takamura, S. Kaneko & A. Fujimura T. MacDonald Effect of azole antifungals ketoconazole and fluconazole Pharmacokinetics on the pharmacokinetics of dexloxiglumide: A.S. Jakate, Pharmacokinetics of insulin aspart in obesity, renal P. Roy, A. Patel, W. Abramowitz, S. Persiani, J. Wangsa impairment, or hepatic impairment: G. Holmes, & R. Kapil L. Galitz, PR. Hu & W. Lyness Prediction of in vivo drug—drug interactions from in Population plasma pharmacokinetics of ''C-flumazenil at vitro data: impact of incorporating parallel pathways of tracer concentrations: CM. van Rij, A.D.R. Huitema, drug elimination and inhibitor absorption rate constant: E.L. Swart H.NJ.M. Greuter, A.A. Lammertsma, H.S. Brown, K. Ito, A. Galetin & J.B. Houston A.C. van Loenen & E.J.F. Franssen Pharmacoepidemiology Pharmacokinetics-Pharmacodynamics Suicide and self-harm following prescription of SSRIs 486 Fluvoxamine impairs single-dose caffeine clearance and other antidepressants: confounding by indication: without altering caffeine pharmacodynamics: R.C. Didham, D.W. McConnell, HJ. Blair & D.M. Reith Therapeutics Short reports 526 General practitioners’ adoption of new drugs and 560 Relationships between sirolimus dosing, concentration previous prescribing of drugs belonging to the same and outcomes in renal transplant recipients: therapeutic class: a pharmacoepidemiological study: C. Dansirikul, S.B. Duffull, R.G. Morris! & S.E. Tett T. Dybdahl, M. Andersen, J. Kragstrup, 1.S. Kristiansen & J. Sendergaard Trimethoprim—sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant Socioeconomic gradient in use of statins among Danish recipients: ¥. Béttiger, C. Brattstrém, L. Backman, patients: population-based cross-sectional study: K. Claesson & J.T. Burke RW. Thomsen, S.P. Johnsen, A.V. Olesen, J.T. Mortensen, H. Baggild, J. Olsen & Mirtazapine-induced arthralgia: A. Passier & H.T. Serensen E. van Puijenbroek Trends in prescribing and utilization of statins and other Favourable dermal penetration of diclofenac after lipid lowering drugs across Europe 1997-2003: administration to the skin using a novel spray gel T. Walley, P. Folino-Gallo, P. Stephens & E. Van Ganse formulation: M. Brunner, P. Dehghanyar, B. Seigfried, on behalf of the EuroMedStat group W. Martin, G. Menke & M. Miiller Adverse drug effects Letter to the editor Calcium antagonists and deep gingival pockets in the Topiramate in non-approved indications and acute population-based SHIP study: PR Meisel, C. Schwahn, myopia or angle closure glancoma: G. Cereza, U. John, H.K. Kroemer & T. Kocher C. Pedrés, N. Garcia & J.-R. Laporte Volume 60, Number 6, December 2005 Editors’ view Gender specific association of CYP2C9*3 with Physiologically based pharmacokinetic modelling: a hyperlipidaemia in Chinese: C-H. Luo, A. Wang, sound mechanistic basis is needed: L. Aarons R.-H. Zhu, W-X. Zhang, W. Mo, B.-N. Yu, G.L. Chen, D.-S. Ou-Yang, X.-H. Duan, A.M.A. El-Aty & H.-H. Zhou Pharmacokinetics and Pharmacodynamics Physiologically based pharmacokinetic modelling of the Drug Disposition three-step metabolism of pyrimidine using '°C-uracil as Sulphation of o-desmethylnaproxen and related an in vivo probe: S. Ito, I Kawamura, M. Inada, compounds by human cytosolic sulfotransferases: ¥. Inoue, Y¥. Hirao, T. Koga, J.-l. Kunizaki, T. Shimizu & C.N. Falany, P. Strém & S. Swedmark H. Sato Pharmacoepidemiology Semi-mechanistic pharmacokinetic/pharmacodynamic Dramatic change in prescribing of hormone modelling of the antimalarial effect of artemisinin: replacement therapy in the Netherlands after T. Gordi, R. Xie & WJ. Jusko publication of the Million Women Study: a follow-up study: A. Faber, M.L. Bouvy, L. Loskamp, Assessment of different methods of inhalation from PB. van de Berg, T.C.G. Egberts & salbutamol metered dose inhalers by urinary drug L.TW. de Jong-van den Berg excretion and methacholine challenge: H.S. Tomlinson, S.A. Corlett, M.B. Allen & H. Chrystyn Therapeutics Usage of paracetamol-containing combination Vasodilator effects of the endothelin ET, receptor analgesics remains high in primary care: C. Usher, selective antagonist BMS-193884 in healthy men: M. Teeling, K. Bennett, B. McGowan & J. Feely N. Dhaun, FE. Strachan, D.E. Newby, N.R. Johnston, N.F. Ford, LL. Hammett M. Palmisano & DJ. Webb Adverse drug effects Obstacles and solutions for spontaneous reporting of Pharmacogenetics adverse drug reactions in the hospital: A. Vallano, Polymorphisms in genes encoding acetylsalicylic acid G. Cereza, C. Pedrds, A. Agusti, |. Danés, C. Aguilera & metabolizing enzymes are unrelated to upper JM. Arnau gastrointestinal health in cardiovascular patients on acetylsalicylic acid: M.G.H. van Oijen, S. Huybers, Short report WH.M. Peters, J.RH. Drenth, RJ.F. Laheij, Effects of grapefruit juice on the pharmacokinetics of EWA. Verheugt & J.B.M.J. Jansen acebutolol: JJ. Lilja, K. Raaska & PJ. Neuvonen Letters to the editors 669 Ocular side-effects of tolterodine and oxybutynin, a 664 Nasal septal perforation enlargement related to topical single-blind prospective randomized trial: ocular steroids: M.Y. Chiang & P. Shah R. Altan-Yaycioglu, O. Yaycioglu & Y.A. Akova 666 Interstitial pneumonitis during lamotrigine therapy: 670 Proceedings of the Dutch Society of Clinical Pharmacology and Biopharmacy meeting of April N. Saravanan, O.M. Otaiku & R.N. Namushi 13th 2005 668 Ocular side-effects of tolterodine and oxybutynin, a 684 Indices for Volume 60 single-blind prospective randomized trial: D.YL. Leung, ¥YY. Kwong & D.S.C. Lam 692 Reviewers for 2005